Five-nation breast cancer study chooses Agilent Technologies Microarrays as primary genomic screening tool

摘要

The researchers will use the microarrays over three years to study gene-expression profiles of 3000 women with Stage 2 and Stage 3 breast cancer to achieve "a better understanding of cancer incidence and mortality in the diverse populations that make up Latin America," according to the US-LACRN.